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Abstract   
Receptor-induced apoptosis is a complex signal transduction pathway involving 
numerous protein/protein interactions and post-transcriptional modifications. The 
response to death receptor stimulation varies significantly from one cell line to 
another and even from one cell to another within a given cell line. In this context, it is 
often difficult to assess whether the molecular mechanisms identified so far are 
sufficient to explain the rich quantitative observations now available, and to detect 
possible gaps in our understanding. This is precisely where computational systems 
biology approaches may contribute. In this chapter, we review studies done in this 
direction, focusing on those that provided significant insight on the functioning of this 
complex pathway by tightly integrating experimental and computational approaches.  
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induced apoptosis, modeling cell types, modeling phenotypic heterogeneity 
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1. Introduction 
Apoptosis is a form of programmed cell death conserved among metazoans playing 
a central role in development and involved in many diseases. Notably, most 
successful non-surgical cancer therapies eventually result in the activation of 
apoptosis in cancer cells [1]. Apoptosis can be triggered internally (via an 'intrinsic' 
pathway) following DNA damage or other intrinsic stimuli, or externally (via an 
'extrinsic' pathway) following the binding of 'death' ligands to 'death' receptors. 
Receptor-induced apoptosis raised therapeutical interest as anti-cancer strategy for 
at least two reasons. Firstly it can be highly selective for certain cell types, ideally 
targeting only cancer cells. Secondly it does not require a functional p53 protein, 
which is frequently mutated in tumor cells, providing resistance to chemotherapeutic 
drugs relying on the DNA damage response. Several death ligand/receptor pairs 
exist. While TNF (and its receptors TNFRs) and CD95L (and its receptor CD95) 
were discovered first, TRAIL (and its receptors DRs) has the highest selectivity 
towards cancer cells [2]. From a largest perspective, the latter is also a reference 
system illustrating how complex circuits involving graded and competing molecular 
signals can generate binary decisions. Because of its high interest, both for systems 
biology and therapeutics, tremendous research efforts have been done to better 
understand its functioning [3–8]. 
The control and regulation of apoptosis involve many genes whose products mediate 
numerous protein/protein interactions, post-translational modifications, transcriptional 
regulations, etc., yielding a highly complex picture. The sensitivity of cells to a given 
death ligand stimulation is multi-factorial, and the effect of genetic perturbations on 
cell survival is highly context-dependent. As a result, the interpretation of results 
obtained on a specific cell line and for a few genetic perturbations or conditions is 
delicate and cannot be readily generalized. The system model paradigm is well 
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suited to deal with this complexity. Computational approaches attempt to integrate 
known mechanisms and interactions into mathematical models, whose predictions 
can be used to propose new experiments for model validation. When applied to 
apoptosis, system level modeling, which started approximately 15 years ago, was 
indeed instrumental in improving our understanding of this complex process. This 
was achieved by tightly integrating data of increasing quality and by increasing the 
scope and/or level of details of models. Excellent reviews discuss these modeling 
works [9–15]. 
Despite these achievements, important fundamental questions remain to be 
answered, especially on the role of phenotypic heterogeneity and how it impacts the 
response to, as well as how it is changed by, treatments by death ligands [16]. Why 
do isogenic cells respond differently to the same amount of death ligand? Indeed, it is 
often the case that not all treated cells die, and when cells die, their death times are 
very heterogeneous. How different from dying cells are surviving cells before 
treatment (i.e. why cells survive)? How different are surviving cells from what they 
were just before treatment (i.e. who are survivors)? Can these differences explain the 
decreased efficiency of subsequent treatments (i.e. what make cells more resistant)? 
Importantly, the two last questions, while critical for understanding the efficiency of 
treatments, are starting to be addressed only since very recently [17, 18]. Here, we 
review the contributions of system modeling studies to our understanding of receptor-
induced apoptosis with a specific focus towards those important questions. We do 
not aim to exhaustively describe all the modeling work done on receptor-induced 
apoptosis. Rather, we describe a few key studies that are highly illustrative of how 
system modeling approaches can provide decisive insights. 
2. Modeling the biochemistry of receptor-induced apoptosis 
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2.1 Early efforts: from known players and reactions to a system model  
 
Many proteins playing a key role in receptor-induced apoptosis are known since 
decades, together with a qualitative picture of how they interact, either to convey 
external death signals to promote the activation of the core executioners of apoptosis 
or on the contrary to act as 'inhibitors' or 'blockers' of death signaling. Figure 1 
provides a schematic overview of apoptotic pathways. 
Despite this qualitative knowledge, how precisely cell response emerges from protein 
interactions in different cell lines and in response to stimulations of different strengths 
was not well understood. This led Fussenegger and colleagues [19], and later 
Eissing and colleagues [20], to quantitatively interpret such qualitative schemes and 
translate them into mathematical models describing the kinetics of the underlying 
biochemical reactions using the simplest quantitative mathematical framework, 
ordinary differential equations (ODEs). Assuming specific values for parameters 
(reaction rate constants and protein initial concentrations) and specific initial 
conditions (initial protein concentrations), these models can be used to simulate the 
temporal evolution of molecular species concentrations. 
These early studies did not quantitatively compared simulation results to data. Their 
explanatory power was therefore not well established. Still, by studying how 
simulated cell behaviors depend on the different parameters, these models provided 
interesting qualitative insights on the structure of the pathways, that is, on the 
molecular implementation of receptor-induced apoptosis. For example, Eissing and 
colleagues rightfully concluded from their model that there must be a caspase-8 
inhibitor to allow for both 1) fast kinetics of apoptosis at sufficient stimulation levels 
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and 2) the existence of a threshold stimuli intensity below which apoptosis is not 
triggered [20]. 
 
Figure 1: Schematic representation of extrinsic and intrinsic apoptosis pathways at the 
molecular level. Only the main actors and interactions are represented. Death ligands bind their 
cognate receptors and promote assembly of DISCs complexes that can lead to the activation of the 
critical initiator caspases caspase-8/10. Initiator caspases can activate effector caspases either 
directly or by promoting the activation of the mitochondrial apoptosis pathway via Bid. This realizes a 
connection with the intrinsic apoptosis pathway, also activating the mitochondrial pathway and 
eventually activating effector caspases. Reprinted from [11], with permission from Elsevier. 
2.2 Tight integration of kinetic modeling and quantitative experimental data 
revealed key mechanistic features of receptor-induced apoptosis 
 
After those early efforts, several groups employed approaches that integrated more 
tightly the construction and analysis of ODE models of receptor-induced apoptosis 
with experimental data. These approaches have been particularly fruitful. Indeed, 
they revealed several key mechanistic features of receptor-induced apoptosis. 
              
8 
 
A pioneering work for the systems biology of apoptosis is the study of CD-95 induced 
apoptosis by Bentele et al. [21]. The authors constructed an ODE-based kinetic 
model combining mechanistic and 'black box' reactions. Their initial model contains 
41 species, 50 unknown parameters and is notably detailed regarding reactions 
taking place at the death-inducing signaling complex (DISC): the requirement for the 
recruitment of two pro-caspase-8 molecules for their activation, as well as the 
competitive recruitment of cFLIP, were detailed. In order to reduce the risks of over-
fitting and detect parameter non-identifiability, the authors used a sensitivity analysis 
approach to reduce model complexity before testing the model against data. In order 
to test the model, they obtained quantitative data characterizing the kinetics of 
caspase activation for several stimulation strengths. The data consisted in 
quantitative western blots corresponding to protein concentrations averaged over the 
cell population. The model predicted a threshold for ligand concentration below which 
no death should be seen, and this prediction was validated experimentally. In the 
model, the existence of this threshold is caused by cFLIP, which incorporates into 
newly assembled DISCs and thus blocks pro-caspase-8 processing. Hence, 
downstream death signaling only occurs for stimulation doses high enough to enable 
the assembly of a sufficient number of DISCs, capable of overcoming this blockade. 
By using an inhibitor of protein synthesis (cycloheximide or CHX) and exploiting 
differences in protein half-lives (cFLIP is short-lived whereas pro-caspase-8 is long-
lived), they decreased cFLIP levels while preserving pro-caspase-8 levels and 
observed the predicted significant decrease of the threshold needed to obtain cell 
death. 
One main limitation of the approach by Bentele and colleagues is the use of 
population-level measurements for quantifying caspase activation. It was already 
known that the kinetics of caspase activation was different in different cells. More 
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precisely, single-cell reporters for probing cytochrome c release [22] and effector 
caspase activation [23] revealed that these events are rapid and relatively invariant in 
terms of duration and intensity from one cell to another and for different stimulus, 
whereas their initiation times are highly variable. An important, although often implicit 
assumption in kinetic models of biochemical pathways is that they represent 
reactions taking place in individual cells: an enzyme in one cell does not catalyze 
reactions in another cell. Therefore, in presence of heterogeneity it is not appropriate 
to reason in terms of population-averaged quantities. Single-cell reporters enabling to 
measure the abundance or activity of biochemical species with live-cell imaging are 
therefore appealing tools to test and interrogate on a proper footing kinetic models. 
And indeed, single-cell reporters in combination with kinetic modeling revealed a 
number of key mechanistic features of receptor-induced apoptosis. 
The first study integrating kinetic modeling with such single-cell data investigated 
apoptosis induced by staurosporine [24]. Although staurosporine does not induce 
apoptosis via death receptors, it triggers MOMP (mitochondrial outer membrane 
permeabilization) and then a rapid, all-or-none effector caspase activation. These 
molecular events form the downstream part of both extrinsic and intrinsic apoptosis 
pathways. The authors focused on the events directly following MOMP, using 
realistic kinetics of cytochrome c and Smac release and apoptosome formation as 
inputs to their model, which then predicted effector caspase activation kinetics. The 
amount of XIAP was found to be a key factor in the kinetics of effector caspase 
activation following MOMP. Interestingly, the model predicted the existence of a 
small range of XIAP concentrations for which MOMP is followed by a slow and partial 
effector caspase activation, a prediction that was then confirmed experimentally.  
Albeck and colleagues were the first to integrate, in a single model, initiator caspase 
activation (via TRAIL binding to death receptors), MOMP regulation and effector 
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caspase activation [25]. The model featured 58 species (native protein and protein 
complexes) and 70 parameters (Figure 2, top left). Instrumental in their work was the 
development of a single-cell reporter for initiator caspase activity [26], which showed 
that this activity slowly rises at a variable rate between cells during the pre-MOMP 
period, and that despite this increasing activity, no significant effector caspase 
activity is observed; the latter arises suddenly and completely following MOMP 
(Figure 2, top right). The model revealed that XIAP enables this all-or-none switching 
behavior not only by competitive binding of caspase 3, but also by promoting its 
degradation via the proteasome (Figure 2, top center). Another mechanistic insight 
brought by this model relates to the role of network topology in generating snap-
action behavior at the level of MOMP (Figure 2, bottom): Bax multimerization and 
mitochondrial transport can quantitatively explain the observed behavior despite the 
presence of Bcl-2, whereas a simple competition model between activated Bax and 
Bcl2 could not. 
Other remarkable works relying on such an integrated approach of quantitative 
experiments with kinetic modeling include the investigation of the activation of NF-B 
signaling in parallel to death signaling in response to CD95-L exposure [27]. 
              
11 
 
 
Figure 2: Key mechanistic features of apoptosis revealed by integrated kinetic modeling and 
single-cell experiments. A relatively complete model of TRAIL-induced apoptosis by Albeck and 
colleagues developed in combination with new single-cell reporters for initiator caspase activity and 
MOMP allowed new mechanistic insights [25]. For example, XIAP control of caspase-3 activity during 
the variable pre-MOMP delay does not rely solely on competitive binding but also on its ability to 
promote caspase-3 proteasomal degradation (right). Another mechanistic insight relates to the role of 
network topology in generating snap-action behavior at the level of MOMP (bottom). Bax 
multimerization and mitochondrial transport can explain observed behavior, as opposed to a simple 
competition model between activated Bax and Bcl2. Figure elements reproduced from [25, 26]. 
3. Modeling populations of individual cells: the role of heterogeneity 
in protein levels 
The previous studies shed light on how snap-action behaviors at the level of MOMP 
and effector caspase activation enable a tightly-constrained all-or-none control over 
apoptosis commitment. Such an all-or-none control is probably beneficial at the 
organism level, because partial effector caspase activation is genotoxic and could 
result it potential harmful mutations. But why different cells from the same cell line 
submitted to the same stimulus in the same conditions trigger MOMP after a highly-
variable delay from one another? Also, in most studies discussed so far, cells were 
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co-treaded with the protein synthesis inhibitor cycloheximide (CHX). Blocking protein 
synthesis is interesting to disentangle the influence of signal transduction pathways 
from the influence of downstream genetic regulations. However, in these conditions, 
all cells eventually die, whereas in normal conditions, a fraction of the cell population 
often survives, a property of vital importance in the context of therapy. What are the 
origins of fractional killing? Are the mechanisms responsible for MOMP timing 
variability in treatments with CHX also involved in fractional killing without CHX? 
An important study from the Sorger group brought key insights into these questions 
[28]. Using live-cell microscopy, the authors followed the fate of individual HeLa cells 
after exposure to TRAIL+CHX or TRAIL alone treatments. In both conditions, a 
significant variability was observed, in death times for TRAIL+CHX treatments, and in 
cell fate and death times for TRAIL alone treatments. Importantly, to investigate the 
role of differences in cell state that exist across cells at the time of treatment in 
determining cell fate and death times, they recorded normal cell proliferation for a 
duration of about one cell cycle before applying the treatment in order to identify 1) 
pairs of cells that are sisters and 2) how much time elapsed between their division 
and treatment. Such lineage information was exquisitely insightful (note that similar 
experimental observations were made earlier by Rehm et al. [29] and later by Bhola 
and Simons [30]). First, in the TRAIL+CHX treatment, recently divided sister cells 
displayed a strong correlation in their death time, despite the high overall variability of 
death time among cells. This established that 1) death time variability is caused by 
pre-existing differences, conserved at cell division; and 2) in presence of CHX, TRAIL 
signaling is almost entirely deterministic (but again, depends on pre-existing 
differences). In other words, because one could accurately predict the fate of one 
recently-divided cell by observing the fate of its sister, there is no significant 
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randomness in the signaling reactions taking place between TRAIL+CHX exposure 
and apoptosis commitment. 
This led Spencer and colleagues to the hypothesis that differences in initial levels for 
proteins involved in TRAIL apoptotic signaling are the main determinants of cell fate 
variability. Mathematical modeling was used to test further this hypothesis (Figure 3). 
They relied on the same kinetic ODE model (with minor modifications) of the protein-
protein reactions mediating TRAIL apoptotic signaling as in their previous study [25]. 
However, instead of using a single population-averaged value for the initial level of 
each protein in the pathway, they created an in silico cell population by sampling 
many times protein levels from distributions, meant to reproduce the natural 
variability in protein levels within a population of HeLa cells (some of those 
distributions were actually measured experimentally using immuno-fluorescence and 
flow cytometry). Good agreement between model predictions and data for 
TRAIL+CHX treatments was then obtained (Figure 3), therefore supporting that in 
these conditions initial variability in protein levels are the main determinants of the 
observed death time variability. 
Additionally, when considering pairs of sister cells born long before TRAIL+CHX 
treatments, the correlation between their death times continuously decreases, 
showing that the cell determinants setting this death time fluctuate over time with a 
timescale of the order of a cell cycle. Notably, protein levels in human cells have 
been shown to fluctuate with similar time scales [31]. It is therefore probable that the 
natural slow fluctuations of protein levels are responsible for the decorrelation of 
sister cell fates after their division. For TRAIL alone treatments, a similar effect is 
seen, but firstly the correlation for recently-divided cells is reduced compared to 
TRAIL+CHX treatments, and secondly this correlation decreases markedly faster 
with sister cells’ age. Because the primary effect of CHX is to block protein synthesis, 
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this also strongly suggests that cell fate variability in TRAIL-induced apoptosis 
originates from synthesis-induced fluctuations in protein levels. 
Note that by nature, the model used by Sorger and colleagues cannot account for the 
sister cell data, a limitation inherent to all deterministic models in which cell-to-cell 
differences are static, that is, cell-to-cell differences are modeled by distributions of 
values for initial protein concentrations or for time-invariant parameters. Such models 
do not explain how cell-to-cell variability can be generated, which is indispensable if 
re-establishment of cell-to-cell variability after TRAIL application should be 
understood. A prime candidate for the (re)generation of cell heterogeneity is 
stochastic protein fluctuations that are missed out in the previous approach. Note 
also that no attempt to reproduce cell fate variability data in TRAIL alone treatments, 
a critical observation, was made. One can cite two reasons. Firstly, the model was 
trained against TRAIL+CHX data, removing the influence of many parameters 
constraining protein production. Secondly, fractional killing was thought to result 
mostly from the activation of survival pathways and these pathways were not 
included in the model. 
Among the other modeling studies investigating cell-to-cell variability in receptor-
induced apoptosis, it is worth mentioning the work by Toivonen and colleagues [32]. 
These authors extended the model of CD-95L induced apoptosis from [21] with 
variable synthesis and degradation rates for the short-lived protein c-FLIP, and their 
analysis predicted c-FLIP targeted degradation as being a fundamental determinant 
of death receptor responses, in agreement with experimental observations. 
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Figure 3: Initial variability in protein levels explains variability in the timing of death. Spencer 
and colleagues combined a previously-proposed ODE model of TRAIL-induced apoptosis signaling 
with the use of distributions for the initial values of proteins levels as could be measured by 
immunochemistry and flow cytometry to represent the heterogeneity in protein levels existing in cell 
populations [28]. Then they recorded the variability in the timing of death for different doses of TRAIL 
and in presence or absence of cycloheximide within the in silico cell population. The resulting 
distributions closely resemble the distributions obtained from experimental data. Figure elements 
reproduced from [28].  
4. Modeling different cell lines and their different sensitivities to 
receptor-induced apoptosis 
From the discussion in the previous section, we have seen that differences in protein 
levels could be a main determinant of cell fate differences. Thus, knowing the 
expression levels of the proteins involved in extrinsic apoptosis in a given cell line 
could help predicting its sensitivity to different death ligand stimulations. Stated 
              
16 
 
differently, we adopt here the viewpoint in which cell lines do not differ by the 
topology of their pathways but rather by the levels or more specifically by the 
distributions of the proteins involved in these pathways. This idea motivated another 
study by the Sorger group  [33]. Using their previous model as a reference for the 
rates of biochemical reactions of extrinsic apoptosis, they studied the biochemical 
basis of the Type I / Type II behaviors. Type I (II) behavior refers to cells that do not 
require (do require) MOMP to commit to apoptosis after death ligand stimulation. As 
a consequence, a strong over-expression of Bcl2 proteins renders cells resistant to 
death ligand stimulation only in type II cells. 
The authors could successfully classify the Type I/II behavior of a set of cell lines 
solely based on the expression levels of the proteins involved in apoptotic signal 
transduction. Their approach was based on direct finite-time Lyapunov exponent 
(DLE) analysis, which measures the influence of changes in initial protein 
concentration on the future states of the system. More precisely, when computing 
DLEs for different initial conditions, they obtained a narrow region of high DLE 
values, i.e. a region where small changes in initial conditions lead to large deviations 
in cell state after stimulation, separating two large regions having comparatively low 
DLE values (Figure 4, bottom left). When positioning cell lines on this space based 
on measured expression levels, they found that Type I and Type II cell lines were on 
opposite sides of the high-DLE region, while cell lines exhibiting mixed behaviors 
were close to it. 
One limitation of the DLE analysis is that the DLE is a number that is difficult to 
interpret. It reflects a sensitivity of the future states to the initial conditions, but it does 
not give information about what is perturbed in the states. In addition, one has to 
choose a time horizon to compute DLEs, which might have a strong influence on the 
results. We have therefore proposed another approach, based on Signal Temporal 
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Logic (STL) instead of DLE [34]. Temporal logics are flexible property specification 
languages that allow describing expected features of behaviors. Experimentally-
observed behaviors are explicitly encoded in STL. This approach allowed us to 
discover that the notion of Type I and Type II has limits, as there exist several 
interpretations of being a Type I or a Type II cell which are not equivalent (Figure 4, 
bottom right). 
The idea that differences in protein expression levels between cell lines could predict 
differences in response to death ligand stimulation from a mechanistic model of 
extrinsic apoptosis was also used in other studies [35]. Recently, a similar approach 
was applied to patient-derived cell lines to predict their sensitivity to treatment [36], 
although here they used statistical modeling (rather than mechanistic modeling) to 
map expression profiles to sensitivity. 
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Figure 4: Simulating the differential sensitivity of cancer cell lines to receptor-induced 
apoptosis. Different cell lines express extrinsic apoptosis proteins at different levels (leading to 
different distributions of single-cell level expression), and those differences a priori impact on their 
response to receptor stimulation. Aldridge and colleagues [33] used Lyapunov exponent analysis to 
study and demonstrated its ability to classify and compare different cell lines. Stoma and colleagues 
[34] proposed an alternative to Lyapunov exponents, Signal Temporal Logic (STL), that allows to 
formally encode behavioral differences as measured by various experimental assays. Figure elements 
reproduced from [33, 34]. 
5. Modeling fluctuations of protein levels to extend the temporal 
scope of existing models 
Until now, the modeling approaches we have discussed represent the naturally-
arising differences in protein levels between individual cells of a given cell line by 
static distributions, and such distributions are then used as initial conditions for 
deterministic models of extrinsic apoptosis signaling (see Section 3). In particular, 
one of the most important mechanisms that generate these distributions, the 
burstiness of gene expression and therefore the stochastic nature of protein turnover, 
is not accounted for in the above-mentioned models. Whether such fluctuations are 
responsible for the observed decrease of the correlation of death times of sister cells 
with their age at treatment as discussed in Section 3 is an interesting question. Not 
accounting for protein fluctuations fundamentally limits the temporal scope of a given 
protein-protein interaction model, even if its kinetic parameters are appropriately 
constrained. With this approach, we addressed the question of what are surviving 
cells after treatment, and hence what will be their resistance to future treatment 
applications (Figure 5, top) [18]. It relies on modeling stochastic gene expression 
(stochastic switches of the promoter between an active and an inactive 
transcriptional state, and stochastic production and degradation of the mRNA) and 
protein turnover for all (native) proteins appearing in the model. As a result, protein 
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levels slowly fluctuate in each individual cell such that, overall, the distributions of the 
protein concentrations in the whole cell population are the ones observed in [28]. 
This means that the naturally-occurring cell-to-cell variability, previously accounted 
by pre-determined distributions for initial protein concentrations, is now an emerging 
property of the model. 
While such model extension a priori introduces many unknown parameters, we found 
that using simple constraints from the literature on parameter values one readily 
obtains good approximations of protein fluctuations for most proteins. Only short-
lived proteins necessitate particular attention. This finding is a cornerstone of the 
approach, as it allows to strongly reduce the number of unconstrained parameters, 
facilitating exploration of the parameter space and reducing the risks of over-fitting. 
We applied this modeling approach to extend the model of TRAIL-induced apoptosis 
used by Spencer and colleagues. Among the 17 native proteins appearing in the 
model, only gene expression parameters for Flip and Mcl1 (known to be very short-
lived at both the mRNA and protein levels) were used for fitting the data, while 
standard parameter constraints were used for all others. The model could 
quantitatively fit cell death distributions and cell survival fractions for both 
TRAIL+CHX and TRAIL alone treatments (Figure 5, middle, left). Moreover, sister 
cell data (decrease in their death time correlation as they age) that have not been 
used to fit our model could be predicted (Figure 5, middle, right), thus validating the 
approach. 
The finding that cell survival does not require TRAIL-induced activation of survival 
pathways, but can occur solely from the interplay of stochastic gene expression, fast 
turnover of certain anti-apoptotic proteins, Flip and Mcl1, and rapid degradation of 
activated forms challenges the classical view about the role of survival pathways in 
              
20 
 
response to TRAIL [37]. While it does not mean that survival pathways do not play a 
role in cell survival after TRAIL exposure, our results strongly suggest that they are 
not the sole contributors to cell survival. 
Finally, because the model can predict changes in cell states (ie cell protein content) 
of the population caused by a first treatment as well as the recovery of cells to their 
normal states (ie initial protein distributions) after treatment based on stochastic gene 
expression and protein turnover, the efficiency of a second treatment as a function of 
the time between treatments could be investigated. In agreement with data, 
simulations showed a marked but transient increase of the population resistance 
after a treatment (Figure 5, bottom). We therefore provide a simple mechanistic 
explanation to the observed reversible resistance of cells to repeated treatments. 
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Figure 5: Systematic, parsimonious modeling of stochastic gene expression together with 
TRAIL apoptotic signaling explains fractional killing and predicts transient cell fate inheritance 
and transient resistance acquisition. (A) Schematic description of the modeling approach. (B) 
Results of the approach when applied to model and data of Spencer and colleagues [28]. (C) 
Simulation of consecutive TRAIL treatments reproduces the observed transient resistance acquisition 
[18]. Figure elements reproduced from [18]. 
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6. Conclusions and perspectives 
In this chapter, we have surveyed how system modeling of receptor-induced 
apoptosis has been instrumental in improving our understanding of this process at 
several levels: the molecular level, the level of cellular decisions between life and 
death, and the level of cell populations exhibiting various degree of resistance as a 
function of their protein expression profiles or their treatment history.  
More precisely, ordinary differential equations models recapitulating known reactions 
between proteins during apoptosis signaling are useful when compared to short-term 
(a few hours) population data about protein level and state kinetics (Section 2). They 
allow verifying that the structure of known reactions is compatible with what is 
experimentally observed and can provide estimates of the associated biochemical 
rates (although parameter non identifiability often prevents the obtention of unique 
estimates). Comparing model predictions with population data has fundamental 
limitations, and comparison to single-cell data (obtained by means of cell-level 
reporters for well-defined biochemical activities or events) is a priori more 
meaningful. Indeed, in the context of receptor-induced apoptosis, it has revealed 
important kinetic features regarding MOMP regulation and effector caspase 
activation (Section 2).  
Still, there are two difficulties arising when comparing ODE models of protein-protein 
reactions with such single-cell data. First, protein synthesis, which is noisy and hence 
generates differences from cell to cell, can have an impact on signaling dynamics at 
the protein level. This effect can only be temporally mitigated by using protein 
synthesis inhibitors like cycloheximide. Second, model predictions depend on initial 
conditions, such as the pre-stimulation levels of the protein involved in receptor-
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induced signaling. We have seen that most of the variability in death timing following 
TRAIL (and cycloheximide) treatment can be explained when realistic random 
distributions of initial protein levels are used as initial conditions for an ODE model of 
TRAIL-induced apoptosis signaling (Section 3). This result is important as it 
demonstrates that TRAIL-induced apoptosis signaling is not intrinsically noisy, and 
that cell state (i.e., the levels of apoptosis proteins) differences at treatment time are 
a major determinant of cell fate variability. Indeed, we have seen that the protein 
expression profiles of different cell lines can inform about their sensitivity to extrinsic 
death stimulation when used as initial conditions of a single (i.e. the same for all cell 
lines) ODE model of apoptotic signaling (Section 4). 
However, while cell fate is almost fully determined by cell state at treatment time 
when protein synthesis is blocked, it is only partially the case in normal treatment 
conditions, in which survival of a fraction of the population is often observed. Indeed, 
protein synthesis can interact with receptor-induced signaling and steer cell fate in 
one direction or another. In section 5, we have seen how systematic but parameter-
parsimonious modeling of stochastic gene expression within ODE models of signal 
transduction dynamics can explain important observations on the dynamics of cell-to-
cell variability in TRAIL-induced apoptosis. This approach allows extending the 
temporal scope of ODE models of receptor-induced apoptosis. This is required to 
investigate the response of cell populations to multiple treatments separated in time, 
for which resistance acquisition is very often observed. An important prediction of 
such models is that transient resistance acquisition can occurs in absence of 
stimulus-induced pro-survival transcriptional activity. 
Despite those promising advances, many questions remain without clear answers. 
For example, while the important role in cell survival of the targeted degradation of 
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many pro- and anti- apoptotic proteins is increasingly recognized [38], accurate 
estimates of the corresponding rates are not available, and to which extent those 
rates fluctuate in single cells and vary from cell to cell is not known. Experiments 
using proteasome inhibitors are difficult to interpret because they have a global (but 
not necessarily identical) effect on all degradation rates. More targeted approaches 
(for example using specific single-cell reporters) could be very useful to better 
understand the role of targeted degradation in receptor-induced apoptosis. 
While current models of receptor-induced apoptosis can be quite large (up to 100 
species and reactions), they are often omitting structural details either because those 
details are not understood very well or because a simplifying representation is 
deliberately preferred. For example, the ligand-induced receptor clustering at cell 
surface, the processing of caspase-8 at the DISC, the role of the different Flip 
isoforms in that processing, and the interactions of all MOMP regulators at the 
mitochondrial surface, are generally significantly simplified. Such simplified 
representations can be accurate and therefore sufficient to address many questions. 
Still, to test and improve our molecular-level understanding of receptor-induced 
apoptosis, more detailed mechanisms can be introduced into existing models, and 
model predictions can be compared to new data generated with adequate tools (such 
as relevant single-cell reporters). Without the 'right' data, increasing model complexity 
is probably vain.   
Finally, while mathematical models of receptor-induced apoptosis start to address the 
question of long-term behavior of cell populations repeatedly treated by death 
receptor agonists, the amount and quality of corresponding experimental data is very 
scarce. Most in-vitro studies still only measure the efficiency of one-time treatment to 
model cell lines, and repeated treatments are only seen in mouse xenografts studies, 
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in which time points and measurements are limited, and many effects related to the 
in-vivo context can affect the response. Quantitative population dynamics data (i.e., 
cell proliferation and death rate as a function of time) for cell lines cultured in-vitro 
and submitted to repeated treatments could prove very useful to better understand 
resistance acquisition, and to map it to molecular mechanisms with the aid of 
mathematical models. Also, the potential impact of spatial organization of the cells in 
tumors may generate further inhomogeneities that are not captured by models 
disregarding space, hence a full understanding will eventually have to explore the 
possible effects of space. 
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